ISLAMABAD: GlaxoSmithKline (GSK) has announced that its Chief Executive Officer (CEO) Emma Walmsley will step down at the end of this year. Luke Miels, the company’s chief commercial officer, will assume the responsibilities of CEO from January 1, 2026, and join the company's board on the same date.
Walmsley will remain with the company until September 2026 to support an orderly transition and assist with "challenges related to geopolitics and emerging technologies", as per the company's announcement. She will continue to receive her salary, pension, and benefits during this period.
Emma Walmsley’s tenure and legacy
Appointed in 2017, Emma Walmsley led GSK through significant changes, including a risky move to demerge its consumer healthcare division, Haleon, in 2022. Haleon manages major brands, such as Sensodyne and Panadol.
Under her leadership, GSK focused on building up its research and development pipeline and concentrating on specialty medicines like cancer treatments and vaccines. Despite efforts to innovate, including attempts to counter revenue losses from patent expiries, the company did not develop its own Covid-19 vaccine.
Investor confidence was a notable challenge during Walmsley’s tenure. Several activist investors, including Elliott Management, exerted pressure, especially amid concerns about GSK’s drug pipeline and stagnant share price performance. The company also rejected a £50 billion acquisition offer from Unilever during this period.
Possible reasons behind the leadership change
GSK’s official statements suggest that the company aims to enter a "pivotal new phase" beginning in 2026, with sales projected to exceed £40 billion by 2031. The company's board stated that the next CEO must deliver shareholder value and exceed these ambitious growth targets.
The announcement of Luke Miels as the new CEO followed a "rigorous, comprehensive selection process" considering both "internal and external candidates". The company's website stated that the board chose Miels based on his extensive experience in biopharma development and commercialization.
The market reacted positively to the news as well, with GSK shares rising by 2.92% immediately after Miels’s appointment was announced, according to Google Finance.
Luke Miels: New CEO profile
GSK reported that Luke Miels joined the company in 2017 and is currently overseeing its global commercial operations for medicines and vaccines. His expertise spans oncology, respiratory medicine, and vaccine commercialization. Before GSK, he held senior roles at AstraZeneca, Roche, and Sanofi.
GSK’s growth strategy
On its website, GSK detailed its growth strategy, focusing on balancing its portfolio across specialty medicines and vaccines, to achieve a significant growth trajectory by 2031. The company expects total sales to top £40 billion on a risk-adjusted basis.
According to Forbes, GSK recently reported $40.1 billion in revenues, $74.5 billion in assets, and $3.3 billion in profit for the current fiscal year.